IDEAYA Biosciences, Inc. (IDYA)

Over the past six months, IDEAYA Biosciences' stock has gained approximately 37%, with a 52-week range between $13.45 and $39.28. Key events include Citizens JMP initiating coverage with a "Market Outperform" rating in September 2025, participation in investor events, presentation of positive interim Phase 2 data for darovasertib in primary uveal melanoma, reporting positive Phase 1/2 results for darovasertib plus crizotinib in metastatic uveal melanoma, participation in investor relations events in November 2025 and February 2026, providing a business update at the J.P. Morgan Healthcare Conference in January 2026, and having approximately $991.9 million in cash as of June 30, 2025, with an anticipated cash runway into 2029.

Traditional demand seasonality is not applicable to IDEAYA Biosciences, Inc. The demand for its investigational drugs is driven by clinical trial progress, regulatory milestones, and the unmet medical needs of specific cancer patient populations, rather than seasonal fluctuations.

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapeutics for cancer patients with genetically defined cancers, utilizing molecular diagnostics to identify suitable patient populations, primarily focusing on synthetic lethality. Their pipeline includes Darovasertib (PKC inhibitor) in Phase 2/3 trials for cancers with GNAQ or GNA11 gene mutations, IDE397 (MAT2A inhibitor) in Phase 2 trials for solid tumors with MTAP gene deletions, IDE849 (DLL3 antibody-drug conjugate inhibitor) in Phase 1 trials for SCLC and neuroendocrine tumors, IDE275 / GSK959 (Werner Helicase inhibitor) in Phase 1 trials for tumors with high microsatellite instability, IDE161 (PARG inhibitor) in Phase 1/2 trials for tumors with homologous recombination deficiency, and IDE705 / GSK101 (Pol Theta Helicase inhibitor) in Phase 1 trials for tumors with BRCA or other HRD-associated mutations. The company also has preclinical programs and strategic alliances with major pharmaceutical companies such as GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., and Merck.

IDEAYA Biosciences, Inc. is headquartered in South San Francisco, California, and primarily conducts its operations and clinical trials within the United States.

IDEAYA Biosciences' brand reputation over the past year has been largely positive, driven by consistent progress in its clinical pipeline and strategic partnerships. Positive clinical data updates, the U.S. FDA's Breakthrough Therapy Designation for darovasertib, and positive financial outlooks contribute to a strong reputation. There have been no reported events that have negatively impacted IDEAYA Biosciences' reputation in the past year.

IDEAYA Biosciences, Inc. has significant institutional ownership, with 376 institutional owners and shareholders holding approximately 99.15% of shares outstanding as of early February 2026; major holders include Fmr Llc, BlackRock, Inc., and Capital Research Global Investors. Individual and insider ownership accounts for approximately 0.85% of shares outstanding, with recent insider transactions including an acquisition of 1,253 shares and a grant of stock options for 80,000 shares to an officer.